Semaglutide & GLP-1 Medications: What You Need to Know

GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a hormone your gut naturally releases after eating. They produce several effects simultaneously:

Appetite suppression — GLP-1 acts on receptors in the brain's hypothalamus to reduce hunger signals and increase feelings of satiety. Many patients describe simply feeling full faster and thinking about food less.

Slowed gastric emptying — Food moves more slowly from the stomach to the small intestine, prolonging fullness and reducing post-meal blood sugar spikes.

Insulin regulation — These medications improve insulin sensitivity and help regulate blood sugar, making them effective for both weight loss and metabolic health.

Tirzepatide (Mounjaro/Zepbound) adds a second mechanism — GIP receptor agonism — and in trials has shown even greater weight loss than semaglutide alone, with some patients losing 20–25% of body weight.

GLP-1 medications are medically indicated for adults who meet certain criteria, though candidacy involves a full clinical evaluation:

• BMI ≥ 30, or BMI ≥ 27 with a weight-related health condition (type 2 diabetes, hypertension, sleep apnea, etc.)

• History of difficulty losing weight with lifestyle changes alone

• No personal or family history of medullary thyroid cancer or MEN2 syndrome

• Not currently pregnant or planning pregnancy

• No active pancreatitis

You don't need to be severely obese to benefit. Many patients are in the overweight range but carry metabolic risk or have been stuck at a weight plateau for years.

In the landmark STEP trials, patients on semaglutide lost an average of 14.9% of body weight over 68 weeks compared to 2.4% in the placebo group. Tirzepatide trials (SURMOUNT) showed average losses of 20–22%.

Real-world results vary based on starting weight, dose, adherence, and lifestyle factors. Most patients begin to see meaningful results within 4–8 weeks of reaching their maintenance dose.

Equally important is what happens beyond the scale: improvements in blood pressure, cholesterol, blood sugar, joint pain, sleep quality, and energy levels are commonly reported.

Weight loss is typically maintained as long as the medication is continued. If stopped, weight regain is common — which is why a supervised program that addresses nutrition and habits alongside medication produces better long-term outcomes.

The most common side effects are GI-related and occur primarily during dose escalation:

• Nausea (most common, typically mild to moderate and temporary)

• Vomiting or diarrhea

• Constipation

• Fatigue during early dose increases

These side effects are substantially reduced by starting at a low dose and increasing slowly. Most patients find they resolve within a few weeks of reaching a stable dose.

Protein intake is critical during GLP-1 therapy. Rapid weight loss can include muscle mass loss if protein intake and resistance exercise are not prioritized. Our programs address this directly.

At Peak Medical Wellness, your provider monitors your progress at regular intervals, adjusts dosing based on your response, and helps you navigate side effects so you can stay the course.